Last reviewed · How we verify
SL TNX-102 at 2.4 mg
SL TNX-102 at 2.4 mg is a Small molecule drug developed by Tonix Pharmaceuticals, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | SL TNX-102 at 2.4 mg |
|---|---|
| Sponsor | Tonix Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults (PHASE1)
- Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SL TNX-102 at 2.4 mg CI brief — competitive landscape report
- SL TNX-102 at 2.4 mg updates RSS · CI watch RSS
- Tonix Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about SL TNX-102 at 2.4 mg
What is SL TNX-102 at 2.4 mg?
SL TNX-102 at 2.4 mg is a Small molecule drug developed by Tonix Pharmaceuticals, Inc..
Who makes SL TNX-102 at 2.4 mg?
SL TNX-102 at 2.4 mg is developed by Tonix Pharmaceuticals, Inc. (see full Tonix Pharmaceuticals, Inc. pipeline at /company/tonix-pharmaceuticals-inc).
What development phase is SL TNX-102 at 2.4 mg in?
SL TNX-102 at 2.4 mg is in Phase 1.
Related
- Manufacturer: Tonix Pharmaceuticals, Inc. — full pipeline
- Compare: SL TNX-102 at 2.4 mg vs similar drugs
- Pricing: SL TNX-102 at 2.4 mg cost, discount & access